FDMT — 4D Molecular Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $844.51m
- $302.56m
- $20.72m
- 57
- 15
- 35
- 28
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 6.99 | 13.6 | 18 | 3.13 | 20.7 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 57.8 | 70.3 | 89.4 | 113 | 134 |
Operating Profit | -50.8 | -56.7 | -71.3 | -110 | -113 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -49.3 | -56.7 | -71.3 | -107 | -101 |
Net Income After Taxes | -49.3 | -56.7 | -71.3 | -107 | -101 |
Net Income Before Extraordinary Items | |||||
Net Income | -49.3 | -56.7 | -71.3 | -107 | -101 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -49.3 | -56.7 | -71.3 | -107 | -101 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -8.4 | -2.12 | -2.57 | -3.32 | -2.58 |
Dividends per Share |